Ovid Therapeutics Hits New 52-Week High of $2.27 Amid Market Challenges

Ovid Therapeutics, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 2.27 on March 9, 2026. This achievement marks a notable recovery from its 52-week low of USD 0.24, showcasing a substantial upward movement in its stock price. Despite this recent high, Ovid Therapeutics has faced challenges over the past year, with a performance decline of 30.97%, contrasting sharply with the S&P 500's gain of 17.78% during the same period. The company's market capitalization stands at USD 191 million, reflecting its microcap status within the industry. Financial metrics indicate that Ovid Therapeutics is currently loss-making, with a return on equity of -70.39% and a debt-to-equity ratio of -0.54. The stock does not offer a dividend yield, and its price-to-book ratio is 4.28. As Ovid Therapeutics continues to navigate the complexities of the biotechnology landscape, this recent price milestone highlights its current market position.